{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T04:11:46Z","timestamp":1793938306691,"version":"4.8.0"},"reference-count":34,"publisher":"American Association for Cancer Research (AACR)","issue":"3","license":[{"start":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T00:00:00Z","timestamp":1772409600000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"University Cancer Foundation via the Institutional Research Grant at MD Anderson Cancer Center"},{"DOI":"10.13039\/100007313","name":"University of Texas MD Anderson Cancer Center","doi-asserted-by":"publisher","award":["NIH\/NCI P30 CA016672"],"award-info":[{"award-number":["NIH\/NCI P30 CA016672"]}],"id":[{"id":"10.13039\/100007313","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>The use of glucagon-like peptide-1 receptor agonists (GLP1-RA) for weight loss is increasing; implications in breast cancer survivors remain unclear. This retrospective cohort study evaluated treatment patterns, weight loss, and outcomes in breast cancer survivors receiving GLP1-RA at an academic institution. We evaluated patients with nonmetastatic [ductal carcinoma in situ (DCIS), stage 1\u20133] breast cancer who received GLP1-RA (2005\u20132024). Linear regression models estimated associations between weight change and clinical factors. After excluding DCIS, propensity score matching (1:2) was used to match patients who received GLP1-RA with patients who did not, based on confounding covariates. Kaplan\u2013Meier estimates and log-rank tests compared disease-free survival (DFS) and overall survival (OS) between GLP1-RA users versus nonusers in the subgroup with invasive disease. We identified 1,022 patients; 79% had type 2 diabetes mellitus. The median weight and body mass index at GLP1-RA initiation were 86.8 kg (47.2\u2013175 kg) and 33.5 kg\/m2 (18.9\u201361.8 kg\/m2). In semaglutide or tirzepatide users (442, 43.2%), the median weight change at 3, 6, and 12 months after GLP1-RA initiation was \u22121.9% (\u221213.2% to 14.9%), \u22123.1% (\u221220.2% to 19%), and \u22122.6% (\u221227.8% to 11.5%), respectively. Endocrine therapy and metformin use were associated with weight gain and loss, respectively; invasive disease stage was linked to greater weight loss. GLP1-RA was not associated with DFS, but OS significantly differed between GLP1-RA users (n = 810) and nonusers (n = 1,620; hazard ratio, 0.37; 95% confidence interval, 0.27\u20130.53; P &amp;lt; 0.0001). In conclusion, in this real-world study in breast cancer survivors, GLP1-RA was associated with modest weight loss and improved all-cause survival. Clinical trials are warranted to study GLP1-RA in this population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>This is the largest study describing real-world patterns of GLP1 receptor agonists in breast cancer survivors. Clinical trials should evaluate these agents for weight management as an adjunct to lifestyle interventions and the potential role in cancer control in breast cancer survivors.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-25-0554","type":"journal-article","created":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T15:17:40Z","timestamp":1770909460000},"page":"447-455","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Weight Loss Patterns and Clinical Outcomes of GLP1 Receptor Agonists in Breast Cancer Survivors"],"prefix":"10.1158","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6994-8527","authenticated-orcid":false,"given":"Jasmine S.","family":"Sukumar","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"The University of Texas MD Anderson Cancer Center 1 Division of Cancer Medicine, Department of Breast Medical Oncology, , Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6425-4400","authenticated-orcid":false,"given":"Akshara S.","family":"Raghavendra","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"The University of Texas MD Anderson Cancer Center 1 Division of Cancer Medicine, Department of Breast Medical Oncology, , Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4914-0728","authenticated-orcid":false,"given":"Sarah","family":"Pasyar","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"The University of Texas MD Anderson Cancer Center 2 Department of Biostatistics, , Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4534-2042","authenticated-orcid":false,"given":"Roland L.","family":"Bassett","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"The University of Texas MD Anderson Cancer Center 2 Department of Biostatistics, , Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5711-2404","authenticated-orcid":false,"given":"Debu","family":"Tripathy","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"The University of Texas MD Anderson Cancer Center 1 Division of Cancer Medicine, Department of Breast Medical Oncology, , Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5377-9167","authenticated-orcid":false,"given":"Carlos H.","family":"Barcenas","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"The University of Texas MD Anderson Cancer Center 1 Division of Cancer Medicine, Department of Breast Medical Oncology, , Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7299-0646","authenticated-orcid":false,"given":"Karen M.","family":"Basen-Engquist","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"The University of Texas MD Anderson Cancer Center 3 Department of Health Disparities Research, , Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5475-8509","authenticated-orcid":false,"given":"Banu K.","family":"Arun","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"The University of Texas MD Anderson Cancer Center 1 Division of Cancer Medicine, Department of Breast Medical Oncology, , Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2026,3,2]]},"reference":[{"key":"2026030206445820800_bib1","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"2026030206445820800_bib2","doi-asserted-by":"crossref","first-page":"105998","DOI":"10.1016\/j.cct.2020.105998","article-title":"Improving health engagement and lifestyle management for breast cancer survivors with diabetes","volume":"92","author":"Shelby","year":"2020","journal-title":"Contemp Clin Trials"},{"key":"2026030206445820800_bib3","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1093\/annonc\/mdu042","article-title":"Body mass index and survival in women with breast cancer-systematic literature review and meta-analysis of 82 follow-up studies","volume":"25","author":"Chan","year":"2014","journal-title":"Ann Oncol"},{"key":"2026030206445820800_bib4","first-page":"410","article-title":"Obese breast cancer patients and survivors: management considerations","volume":"32","author":"Sheng","year":"2018","journal-title":"Oncology (Williston Park)"},{"key":"2026030206445820800_bib5","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1093\/jnci\/djab053","article-title":"Body mass index and risk of second cancer among women with breast cancer","volume":"113","author":"Feigelson","year":"2021","journal-title":"J Natl Cancer Inst"},{"key":"2026030206445820800_bib6","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1200\/JCO.2015.64.3809","article-title":"American Cancer Society\/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline","volume":"34","author":"Runowicz","year":"2016","journal-title":"J Clin Oncol"},{"key":"2026030206445820800_bib7","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.2040-1124.2010.00022.x","article-title":"GIP and GLP-1, the two incretin hormones: similarities and differences","volume":"1","author":"Seino","year":"2010","journal-title":"J Diabetes Investig"},{"issue":"Suppl 3","key":"2026030206445820800_bib8","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/dom.14496","article-title":"The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: a pathophysiological update","volume":"23","author":"Nauck","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"2026030206445820800_bib9","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1038\/s41591-024-03412-w","article-title":"Mapping the effectiveness and risks of GLP-1 receptor agonists","volume":"31","author":"Xie","year":"2025","journal-title":"Nat Med"},{"key":"2026030206445820800_bib10","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"7","author":"Kristensen","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026030206445820800_bib11","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"key":"2026030206445820800_bib12","doi-asserted-by":"crossref","first-page":"e2427258","DOI":"10.1001\/jamanetworkopen.2024.27258","article-title":"Clinical outcomes of tirzepatide or GLP-1 receptor agonists in individuals with type 2 diabetes","volume":"7","author":"Chuang","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"Suppl 16","key":"2026030206445820800_bib13","doi-asserted-by":"crossref","first-page":"e13063","DOI":"10.1200\/JCO.2024.42.16_suppl.e13063","article-title":"Evaluating the impact of GLP-1 receptor agonists on weight management in patients with breast cancer undergoing endocrine therapy: a comparative analysis","volume":"42","author":"Urueta Portillo","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026030206445820800_bib14","doi-asserted-by":"crossref","first-page":"3854","DOI":"10.1002\/cncr.34928","article-title":"Incidence, risk factors, and management of alpelisib-associated hyperglycemia in metastatic breast cancer","volume":"129","author":"Shen","year":"2023","journal-title":"Cancer"},{"issue":"Suppl 16","key":"2026030206445820800_bib15","doi-asserted-by":"crossref","first-page":"e24140","DOI":"10.1200\/JCO.2024.42.16_suppl.e24140","article-title":"Impact of semaglutide and tirzepatide administration on weight in women with stage I-III breast cancer","volume":"42","author":"Fischbach","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026030206445820800_bib16","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1002\/sim.3697","article-title":"Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples","volume":"28","author":"Austin","year":"2009","journal-title":"Stat Med"},{"key":"2026030206445820800_bib17","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"key":"2026030206445820800_bib18","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"key":"2026030206445820800_bib19","first-page":"294","article-title":"GLP-1 receptor agonist use and weight change in patients with breast cancer","volume":"7","author":"Shen","year":"2025","journal-title":"Oncology (Williston Park)"},{"key":"2026030206445820800_bib20","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1016\/j.clbc.2017.11.006","article-title":"Determinants of weight gain during adjuvant endocrine therapy and association of such weight gain with recurrence in long-term breast cancer survivors","volume":"18","author":"Raghavendra","year":"2018","journal-title":"Clin Breast Cancer"},{"key":"2026030206445820800_bib21","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1007\/s11764-023-01408-y","article-title":"Factors associated with weight gain in pre- and post-menopausal women receiving adjuvant endocrine therapy for breast cancer","volume":"18","author":"Uhelski","year":"2024","journal-title":"J Cancer Surviv"},{"key":"2026030206445820800_bib22","doi-asserted-by":"crossref","first-page":"10211","DOI":"10.1038\/srep10211","article-title":"Effect of targeted estrogen delivery using glucagon-like peptide-1 on insulin secretion, insulin sensitivity and glucose homeostasis","volume":"5","author":"Tiano","year":"2015","journal-title":"Sci Rep"},{"key":"2026030206445820800_bib23","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1038\/s44161-024-00563-4","article-title":"Immune checkpoint landscape of human atherosclerosis and influence of cardiometabolic factors","volume":"3","author":"Dur\u00e1n","year":"2024","journal-title":"Nat Cardiovasc Res"},{"key":"2026030206445820800_bib24","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1002\/cncr.30104","article-title":"An observational study to examine changes in metabolic syndrome components in patients with breast cancer receiving neoadjuvant or adjuvant chemotherapy","volume":"122","author":"Dieli-Conwright","year":"2016","journal-title":"Cancer"},{"key":"2026030206445820800_bib25","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1007\/s13679-019-00335-3","article-title":"Metformin: mechanisms in human obesity and weight loss","volume":"8","author":"Yerevanian","year":"2019","journal-title":"Curr Obes Rep"},{"key":"2026030206445820800_bib26","doi-asserted-by":"crossref","first-page":"e2421305","DOI":"10.1001\/jamanetworkopen.2024.21305","article-title":"Glucagon-like peptide 1 receptor agonists and 13 obesity-associated cancers in patients with type 2 diabetes","volume":"7","author":"Wang","year":"2024","journal-title":"JAMA Netw Open"},{"key":"2026030206445820800_bib27","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1001\/jamaoncol.2023.5573","article-title":"GLP-1 receptor agonists and colorectal cancer risk in drug-naive patients with type 2 diabetes, with and without overweight\/obesity","volume":"10","author":"Wang","year":"2024","journal-title":"JAMA Oncol"},{"key":"2026030206445820800_bib28","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1210\/clinem\/dgaa891","article-title":"Do GLP-1 receptor agonists increase the risk of breast cancer? A systematic review and meta-analysis","volume":"106","author":"Piccoli","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"2026030206445820800_bib29","first-page":"i5340","article-title":"Glucagon-like peptide-1 analogues and risk of breast cancer in women with type 2 diabetes: population based cohort study using the UK Clinical Practice Research Datalink","volume":"355","author":"Hicks","year":"2016","journal-title":"BMJ"},{"key":"2026030206445820800_bib30","doi-asserted-by":"crossref","first-page":"2647","DOI":"10.1007\/s13277-015-4104-9","article-title":"Antidiabetic exendin-4 activates apoptotic pathway and inhibits growth of breast cancer cells","volume":"37","author":"Fidan-Yaylal\u0131","year":"2016","journal-title":"Tumour Biol"},{"key":"2026030206445820800_bib31","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ygyno.2024.10.004","article-title":"Tirzepatide as an innovative treatment strategy in a pre-clinical model of obesity-driven endometrial cancer","volume":"191","author":"Kong","year":"2024","journal-title":"Gynecol Oncol"},{"key":"2026030206445820800_bib32","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.3390\/ijms24021703","article-title":"GLP-1 receptor agonists in non-alcoholic fatty liver disease: current evidence and future perspectives","volume":"24","author":"Nevola","year":"2023","journal-title":"Int J Mol Sci"},{"key":"2026030206445820800_bib33","doi-asserted-by":"crossref","first-page":"e221169","DOI":"10.1001\/jamanetworkopen.2022.1169","article-title":"Association of glucagon-like peptide-1 receptor agonist vs dipeptidyl peptidase-4 inhibitor use with mortality among patients with type 2 diabetes and advanced chronic kidney disease","volume":"5","author":"Chen","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2026030206445820800_bib34","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s10549-010-1248-6","article-title":"Aberrant expression of DNA damage response proteins is associated with breast cancer subtype and clinical features","volume":"129","author":"Guler","year":"2011","journal-title":"Breast Cancer Res Treat"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-25-0554\/3737674\/crc-25-0554.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/3\/447\/3744463\/crc-25-0554.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/3\/447\/3744463\/crc-25-0554.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T11:45:09Z","timestamp":1772451909000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/6\/3\/447\/774930\/Weight-Loss-Patterns-and-Clinical-Outcomes-of-GLP1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,1]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-25-0554","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.31444534","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31444525","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31444537","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31444528","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31444519","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31444540","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31444531","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31444543","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31444522","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.8332417","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,1]]}}}